NKTX
Company Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 115,385 | 6.55M |
| Net Income | (104.08M) | (108.79M) | (117.50M) | (113.84M) | (86.08M) | (91.36M) | (21.08M) | (274,503) |
| EPS | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 | -1.59 | -2.55 | -0.01 |
| Free Cash Flow | (89.91M) | (104.11M) | (114.31M) | (104.11M) | (72.95M) | (51.02M) | (20.30M) | (5.94M) |
| FCF / Share | -1.22 | -1.53 | -2.33 | -2.39 | -2.22 | -1.60 | -2.26 | -0.12 |
| Operating CF | (88.70M) | (99.70M) | (86.16M) | (57.00M) | (67.93M) | (43.51M) | (18.37M) | (5.18M) |
| Total Assets | 404.21M | 501.20M | 378.88M | 472.94M | 273.90M | 337.65M | 48.41M | 9.61M |
| Total Debt | 76.42M | 80.27M | 88.34M | 82.93M | 12.46M | 8.92M | 7.30M | 12.71M |
| Cash & Equiv | 39.63M | 27.87M | 31.04M | 37.49M | 60.82M | 96.69M | 20.61M | 7.87M |
| Book Value | 312.32M | 407.98M | 273.29M | 372.21M | 250.97M | 321.22M | (25.48M) | (5.40M) |
| Return on Equity | -0.33 | -0.27 | -0.43 | -0.31 | -0.34 | -0.28 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (27.83M) | (27.41M) | (21.71M) | (22.98M) | (31.98M) | (25.93M) | (28.34M) | (24.99M) | (29.52M) | (27.75M) | (25.64M) | (33.29M) |
| EPS | -0.37 | -0.37 | -0.29 | -0.31 | -0.43 | -0.35 | -0.39 | -0.34 | -0.58 | -0.57 | -0.52 | -0.68 |
| Free Cash Flow | (28.61M) | (22.21M) | (18.68M) | (18.89M) | (30.13M) | (25.85M) | (25.32M) | (24.25M) | (28.68M) | (30.16M) | (26.46M) | (32.10M) |
| FCF / Share | -0.39 | -0.30 | -0.25 | -0.26 | -0.41 | -0.35 | -0.34 | -0.33 | -0.57 | -0.61 | -0.54 | -0.66 |
| Operating CF | (28.20M) | (21.65M) | (18.69M) | (18.75M) | (29.61M) | (24.75M) | (24.55M) | (21.89M) | (28.51M) | (23.35M) | (20.27M) | (21.77M) |
| Total Assets | 372.07M | 404.21M | 427.24M | 448.31M | 470.61M | 501.20M | 532.03M | 554.09M | 576.94M | 378.88M | 405.86M | 429.04M |
| Total Debt | 75.00M | 76.42M | 76.63M | 78.54M | 78.91M | 80.27M | 85.45M | 85.57M | 87.17M | 88.34M | 89.47M | 90.50M |
| Cash & Equiv | 27.36M | 39.63M | 60.11M | 53.41M | 52.60M | 27.87M | 56.96M | 120.40M | 250.28M | 31.04M | 38.26M | 29.12M |
| Book Value | 285.86M | 312.32M | 337.90M | 357.67M | 378.81M | 407.98M | 430.87M | 453.18M | 473.65M | 273.29M | 296.82M | 317.98M |
| Return on Equity | -0.10 | -0.09 | -0.06 | -0.06 | -0.08 | -0.06 | -0.07 | -0.06 | -0.06 | -0.10 | -0.09 | -0.10 |
